SCHEMBL1576833

SCHEMBL1576833

CC(=O)N(Cc1ccccc1)[C@H](COC(C)(C)C)C(N)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
RIPK1 Q13546 2/20 0.40
ALOX5 P09917 1/20 0.39
PTGS1 P23219 1/20 0.39
PTGS2 P35354 1/20 0.39
RAB9A P51151 4/20 0.39
NPC1 O15118 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CA12 O43570 1/20 0.38
CA9 Q16790 1/20 0.38
TRPM8 Q7Z2W7 1/20 0.38
AKT1 P31749 2/20 0.37
HPGD P15428 1/20 0.37
ACHE P22303 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7742273 0.92 MEN1 (0.43) MEN1KMT2AALDH1A1LMNAPOLB
SCHEMBL1577179 0.85 MEN1 (0.44) MEN1KMT2AALDH1A1LMNAPOLB
SCHEMBL28137098 0.85 MEN1 (0.44) MEN1KMT2AALDH1A1LMNAPOLB
SCHEMBL1576811 0.83 ALOX5 (0.46) MEN1KMT2AALDH1A1LMNAPOLB
SCHEMBL1576866 0.80 KMT2A (0.47) MEN1KMT2AALDH1A1LMNAPOLB
SCHEMBL1895976 0.78 KMT2A (0.45) MEN1KMT2AALDH1A1LMNAPOLB
SCHEMBL2490488 0.78 RIPK1 (0.43) MEN1KMT2AALDH1A1LMNAPOLB
SCHEMBL1258469 0.76 ACACB (0.40) MEN1KMT2AALDH1A1LMNAPOLB
SCHEMBL6813227 0.74 KMT2A (0.54) MEN1KMT2AALDH1A1LMNAPOLB
SCHEMBL1577001 0.74 SLC7A5 (0.40) MEN1KMT2ALMNAPOLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853439-B2 Processes for the preparation of lacosamide and intermediates thereof CADILA HEALTHCARE LIMITED (IN) 2014-10-07 US claimed
US-20120209022-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2012-08-16 US claimed
US-9242926-B2 Processes for the preparation of lacosamide and intermediates thereof CADILA HEALTHCARE LIMITED (IN) 2016-01-26 US disclosed
US-8853439-B2 Processes for the preparation of lacosamide and intermediates thereof CADILA HEALTHCARE LIMITED (IN) 2014-10-07 US disclosed
US-20140296572-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2014-10-02 US disclosed
US-20120209022-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2012-08-16 US disclosed
EP-2480524-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF Cadila Healthcare Limited (IN) 2012-08-01 EP disclosed
WO-2011039781-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2011-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120209022-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CA3, TREH, NAAA MEN1 1948/4885KMT2A 494/4885ALDH1A1 916/4885
US-20140296572-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CA3, TREH, NAAA MEN1 1948/4885KMT2A 494/4885ALDH1A1 916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.